Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sheri Moores"'
Autor:
Byoung Chul, Cho, Allison, Simi, Joshua, Sabari, Smruthi, Vijayaraghavan, Sheri, Moores, Alexander, Spira
Publikováno v:
Clinical Lung Cancer. 24:89-97
Substantial therapeutic advancements have been made in identifying and treating activating mutations in advanced non-small cell lung cancer (NSCLC); however, resistance to epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bea02fccf757217bdbd297379b2d605c
https://doi.org/10.1016/j.cllc.2022.11.004
https://doi.org/10.1016/j.cllc.2022.11.004
Autor:
Alessandra Cavaliere, Ziqi Li, Yiyun Huang, Suxia Sun, Supum Lee, Jacob Bodner, Bernadette V. Marquez-Nostra, Sheri Moores
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 48:383-394
Amivantamab is a novel bispecific antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (HGFR/c-MET) that are overexpressed in several types of cancer including triple-negative brea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a78bbc425b2ab1cb037d9fd3dbb25c9e
https://doi.org/10.1007/s00259-020-04978-6
https://doi.org/10.1007/s00259-020-04978-6
Autor:
Thomas Valerius, Paul W. H. I. Parren, Janine Schuurman, Joost J. Neijssen, William R. Strohl, Kristen M. Chevalier, Luus Wiegman, Cardoso Rosa Maria Fernandes, Mark L. Chiu, Sheri Moores, G. Mark Anderson
Publikováno v:
The Journal of Biological Chemistry
Journal of Biological Chemistry, 296. ELSEVIER
Journal of Biological Chemistry, 296. ELSEVIER
A bispecific antibody (BsAb) targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) pathways represents a novel approach to overcome resistance to targeted therapies in patients with nonsmall cell lun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca933b2c86ba6635402921bd327c1a34
https://hdl.handle.net/1887/3256851
https://hdl.handle.net/1887/3256851
Autor:
Hillary Millar, Ryan Lenhart, Kathryn Packman, Benjamin Henley, Sylvie Laquerre, Smruthi Vijayaraghavan, Matthew V. Lorenzi, Lorraine Lipfert, Jocelyn Sendecki, Kristen M. Chevalier, Barbara Bushey, Sheri Moores, Marilda Beqiri
Publikováno v:
Molecular cancer therapeutics. 19(10)
Small molecule inhibitors targeting mutant EGFR are standard of care in non–small cell lung cancer (NSCLC), but acquired resistance invariably develops through mutations in EGFR or through activation of compensatory pathways such as cMet. Amivantam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db4161b3154d2d5f870d891c0cca8ccd
https://pubmed.ncbi.nlm.nih.gov/32747419
https://pubmed.ncbi.nlm.nih.gov/32747419
Autor:
Benjamin Henley, Kristen M. Chevalier, Sylvie Laquerre, Sheri Moores, Matthew V. Lorenzi, Eric B. Haura, Barbara Bushey, Smruthi Vijayaraghaven, Gerald Chu, Matthew Smith, Nataša Obermajer, J.C. Curtin, Kathryn Packman
Publikováno v:
Cancer Research. 81:953-953
Small molecule EGFR inhibitors have proven effective in treatment of Non-Small Cell Lung Cancer (NSCLC) with activating EGFR mutations, however there is minimal to no efficacy in wild-type EGFR NSCLC. Amivantamab, an EGFR/MET bispecific antibody, has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::266ef128b03f7b05e25f07494efff6b3
https://doi.org/10.1158/1538-7445.am2021-953
https://doi.org/10.1158/1538-7445.am2021-953
Autor:
Kristen M. Chevalier, Jocelyn Sendecki, Hillary Millar, Kathryn Packman, Barbara Bushey, Lorraine Lipfert, Sylvie Laquerre, Ryan Lenhart, Marilda Beqiri, Benjamin Henley, Smruthi Vijayaraghavan, Matthew V. Lorenzi, Sheri Moores
Publikováno v:
Journal of Thoracic Oncology. 15:S27-S28
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5ae81c794819a8e635e74088c593923
https://doi.org/10.1016/j.jtho.2019.12.072
https://doi.org/10.1016/j.jtho.2019.12.072
Autor:
Stephen Jarantow, Katharine D. Grugan, Barbara Bushey, Sylvie Laquerre, Jose Pardinas, Keri Dorn, Sheri Moores, Mark L. Chiu
Publikováno v:
mAbs
Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancers acquire resistance to EGFR tyrosine kinase inhibitors through multiple mechanisms including c-Met receptor pathway activation. We generated a bispecific antibody targeting EGF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892d6636c7815d0ea4f7d2aa38db4e23
http://europepmc.org/articles/PMC5240640
http://europepmc.org/articles/PMC5240640
Autor:
Sheri Moores, Barbara Bushey, Benjamin Henley, Kathryn Packman, Matthew V. Lorenzi, Hillary Millar, Sylvie Laquerre, Smruthi Vijayaraghavan, Marilda Beqiri, Lorraine Lipfert, Kristen M. Chevalier, Ryan Lenhart
Publikováno v:
Cancer Research. 80:5651-5651
Small molecule inhibitors targeting EGFR are now standard of care in NSCLC patients harboring EGFR mutations, but acquired resistance invariably develops through secondary mutations within EGFR and/or through activation of compensatory pathways such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b745dfc3f0cd65e2d20fd8de00c0de5
https://doi.org/10.1158/1538-7445.am2020-5651
https://doi.org/10.1158/1538-7445.am2020-5651
Autor:
Sheri Moores, Eilyn R. Lacy, Jose Pardinas, Manuel A. Sepulveda, Ken Boakye, Mark L. Chiu, Barbara Bushey, Renouard Sanders, Stephen Jarantow
Publikováno v:
The Journal of Biological Chemistry
Background: Cancer cells express surface antigens at different levels from normal cells. Results: Differences in EGFR and c-MET receptor density levels influenced the in vitro activity of an EGFR × c-MET bispecific antibody. Conclusion: Consideratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a0783529e37128297c7e245bbb9ec90
https://doi.org/10.1074/jbc.m115.651653
https://doi.org/10.1074/jbc.m115.651653
Autor:
Kristina B. Emdal, Antje Dittmann, Sylvie Laquerre, Sheri Moores, Raven J. Reddy, Rebecca S. Lescarbeau, Forest M. White
Publikováno v:
PMC
Approximately 10% of non–small cell lung cancer (NSCLC) patients in the United States and 40% of NSCLC patients in Asia have activating epidermal growth factor receptor (EGFR) mutations and are eligible to receive targeted anti-EGFR therapy. Despit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3f4f06d0ff0e5be25594f33dbf5f2cd
https://orcid.org/0000-0001-6483-9110
https://orcid.org/0000-0001-6483-9110